Dermata Therapeutics (DRMA) Stock Chart & Stock Price History $6.79 -0.20 (-2.86%) As of 02:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dermata Therapeutics Stock Price Performance The Dermata Therapeutics (DRMA) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 71.48%, with a year-to-date return of -49.93%. In the past month, the stock has increased 1.50%, reflecting recent market activity. As of the latest close, Dermata Therapeutics traded at $6.76 with a market cap of $4.33 million and volume of 34,179 shares. Receive DRMA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+4.81%1 Month Performance+1.50%3 Month Performance-25.54%Year-To-Date Performance-49.93%1 Year Performance-71.48% DRMA Stock Chart for Wednesday, August, 6, 2025 DRMA Chart by TradingView Dermata Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/05/2025$7.06$6.76-4.25%$7.02$6.6034,179 shs$4.33 million08/04/2025$6.45$7.06+9.46%$7.14$6.3461,421 shs$4.11 million08/01/2025$6.23$6.45+3.50%$6.88$6.0197,087 shs$41.14 million07/31/2025$6.12$6.23+1.76%$6.33$5.9421,631 shs$3.98 million07/30/2025$7.06$6.12-13.27%$7.05$6.0835,479 shs$3.91 million07/29/2025$7.03$7.06+0.46%$7.33$6.9025,230 shs$4.50 million07/28/2025$6.99$7.03+0.53%$7.28$6.802,107 shs$4.49 million07/25/2025$6.99$6.99-0.01%$7.11$6.803,247 shs$4.46 million07/24/2025$7.15$6.99-2.13%$7.50$6.8231,298 shs$4.46 million07/23/2025$6.97$7.15+2.51%$7.30$6.844,400 shs$4.56 million Get the Latest News and Ratings for DRMA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/22/2025$6.95$6.97+0.30%$7.17$6.817,729 shs$4.45 million07/21/2025$6.77$6.95+2.64%$7.40$6.4233,989 shs$4.43 million07/18/2025$6.83$6.77-0.88%$7.07$6.546,026 shs$4.32 million07/17/2025$7.01$6.83-2.57%$7.50$6.4613,938 shs$4.36 million07/16/2025$7.30$7.01-4.01%$7.39$6.8827,577 shs$4.47 million07/15/2025$7.29$7.30+0.18%$7.78$7.0016,918 shs$4.66 million07/14/2025$7.10$7.29+2.68%$8.00$6.9226,813 shs$4.65 million07/11/2025$7.20$7.10-1.35%$7.80$6.9116,857 shs$4.53 million07/10/2025$6.50$7.20+10.76%$7.20$6.607,067 shs$4.59 million07/09/2025$6.30$6.50+3.14%$7.07$6.307,992 shs$4.15 million07/08/2025$6.95$6.30-9.35%$6.78$6.1370,571 shs$4.02 million07/07/2025$6.66$6.95+4.35%$7.43$6.4015,642 shs$4.24 million Related Companies SYBX Stock Chart LEXX Stock Chart LPCN Stock Chart BLRX Stock Chart GELS Stock Chart TRIB Stock Chart EDSA Stock Chart ALLR Stock Chart MTEX Stock Chart ATHA Stock Chart Receive DRMA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:DRMA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
